Outlook Therapeutics Inc Stock, NASDAQ:OTLK
485 Route 1 South, Building F, Suite 320, Iselin, New Jersey 08830
United States of America
Number of Employees: 8
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.